EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Role of hypoxia inducible factor/vascular endothelial growth factor/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity

Marwa Monier Mahmoud Refaie iD, Asmaa Ma Bayoumi, Sahar Ahmed Mokhemer, Sayed Shehata, Nahla Mohammed Abd El-Hameed

Human & Experimental Toxicology · 2023

DOI: 10.1177/09603271231193392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human & Experimental Toxicology, 2023. Verfasst von Marwa Monier Mahmoud Refaie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, Egypt. Hauptthemen laut MEDLINE: Cardiotoxicity, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cyclophosphamide (CP) is a commonly used chemotherapeutic and immunosuppressive alkylating agent. However, cardiac adverse effects of CP interfere with its clinical benefit. Cardio-oncology research is currently an important issue and finding effective cardiopreserving agents is a critical need. For the first time, we aimed to detect if dapagliflozin (DAP) could ameliorate CP-induced cardiac injury and investigated the role of hypoxia inducible factor α (HIF1α)/vascular endothelial growth factor (VEGF)/endothelial nitric oxide synthase (eNOS) pathway.

Methods

Forty male Wistar albino rats were included in the current model. Studied groups are: control group; CP-induced cardiotoxicity group; CP group treated with DAP; CP group treated with DAP and administered a nitric oxide synthase inhibitor; nitro-ω-L-arginine (L-NNA) before DAP to explore the role of eNOS.

Results

Our data revealed that CP could induce cardiac damage as manifested by significant increases in cardiac enzymes, blood pressure, malondialdehyde (MDA), tumor necrosis factor alpha (TNFα), HIF1α, sodium glucose co-transporter 2 (SGLT2) and cleaved caspase-3 levels with toxic histopathological changes. However, there are significant decreases in reduced glutathione (GSH), total antioxidant capacity (TAC), VEGF, and eNOS. On the opposite side, co-administration of DAP showed marked improvement of CP-induced cardiac damage that may be due to its ability to inhibit SGLT2, antioxidant, anti-inflammatory and anti-apoptotic properties. Results showed decreasing the cardioprotective effect of DAP on administration of L-NNA, reflecting the critical effect of eNOS in mediating such protection.

Conclusion

DAP could reduce CP cardiotoxicity based upon its ability to modulate SGLT2 and HIF1α/VEGF/eNOS signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityVascular Endothelial Growth Factor ARatsAnimalsMaleNitric Oxide Synthase Type IIIAntioxidantsSodium-Glucose Transporter 2Nitric Oxide SynthaseSignal TransductionRats, WistarCyclophosphamideHypoxiaNitric OxideBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

Dapagliflozincardiotoxicitycyclophosphamideendothelial nitric oxide synthasevascular endothelial growth factor

Substanzen

Vascular Endothelial Growth Factor ANitric Oxide Synthase Type IIIAntioxidantsSodium-Glucose Transporter 2Nitric Oxide SynthaseCyclophosphamideNitric OxidedapagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
  • Department of Histology and Cell Biology, Faculty of Medicine, Minia University, El-Minia, Egypt.
  • Department of Cardiology, Faculty of Medicine, Minia University, El-Minia, Egypt.

ORCID-Profile: Marwa Monier Mahmoud Refaie

Zitieren

APA

Mahmoud Refaie, M. M., Bayoumi, A. M., Mokhemer, S. A., Shehata, S., & Abd El-Hameed, N. M. (2023). Role of hypoxia inducible factor/vascular endothelial growth factor/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity. Human & Experimental Toxicology. https://doi.org/10.1177/09603271231193392

Vancouver

Mahmoud Refaie MM, Bayoumi AM, Mokhemer SA, Shehata S, Abd El-Hameed NM. Role of hypoxia inducible factor/vascular endothelial growth factor/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity. Human & Experimental Toxicology. 2023. doi:10.1177/09603271231193392

BibTeX
@article{MahmoudRefaie2023,
  author = {Mahmoud Refaie, Marwa Monier and Bayoumi, Asmaa Ma and Mokhemer, Sahar Ahmed and Shehata, Sayed and Abd El-Hameed, Nahla Mohammed},
  title = {Role of hypoxia inducible factor/vascular endothelial growth factor/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity},
  journal = {Human & Experimental Toxicology},
  year = {2023},
  doi = {10.1177/09603271231193392}
}
Kostenlos starten →